Four things you should know about the pending Charter challenge against Medicare

By Colleen Flood and Kathleen O’Grady, EvidenceNetwork.ca A version of this commentary appeared in the Globe and Mail, the Medical Post and the Windsor Star A long-running dispute between Dr. Brian Day, the co-owner of Cambie Surgeries Corporation and the British Columbia government may finally be resolved in the BC Supreme Court next year — and the ruling could transform the

Take part in CCSN’s important survey on Xgeva!

The purpose of this survey is to provide the Canadian Cancer Survivor Network (CCSN) with insights and perspectives about the use of denosumab (Xgeva) for the prevention of skeletal-related events due to bone metastases from solid tumours. The information gathered from this survey will be used in order to prepare a patient evidence submission to

Finding Flexible Work Difficult for Cancer Patients and Caregivers

New data released on financial, decision-making and emotional burden of cancer LAVAL, Quebec, January 14, 2014 – A 2013 Léger national survey of cancer patients and their caregivers, commissioned by Sanofi Canada, sheds new light on the striking financial, decision-making and emotional burden the disease puts on cancer patients and their caregivers.  The survey finds that

ZYTIGA™* (abiraterone acetate) receives Health Canada approval for treatment for metastatic prostate cancer

First Oral Treatment for Metastatic Prostate Cancer That Inhibits Androgen Production at All Three Sources Toronto, ON, July 28, 2011– Janssen Inc. announced today that after a priority review, Health Canada has approved ZYTIGA™ (abiraterone acetate), an oral medication for the treatment of men with metastatic prostate cancer. ZYTIGA™ is indicated with prednisone for the